Extended Double Plasma Molecular Adsorption Sessions and Bilirubin Clearance: A Case Report.

Hemodial IntJul 3, 2026 (epub)
Case ReportNephrology

Hui Ye, Yi Long Hao, Hai Nan Yang et al.

✦ AI-curated · Sources linked

Case in brief

A 51-year-old male with hyperbilirubinemia underwent two extended sessions of double plasma molecular adsorption treatment, each lasting over 6 hours and utilizing more than 10 L of plasma. Total bilirubin clearance was 44.6% in the first session and 34.6% in the second. The study highlighted that clearance peaked when the plasma adsorption volume matched the patient's plasma volume, with diminishing returns observed beyond this point.

Diagnostic / clinical pearl

Clinicians should note that maximizing plasma adsorption volume relative to the patient's plasma volume can optimize bilirubin clearance during double plasma molecular adsorption treatments.

Why it matters

Understanding the relationship between plasma adsorption volume and bilirubin clearance can guide treatment protocols and resource management in patients with hyperbilirubinemia.

Source

PubMed · PMID 42396628

Published in Hemodial Int. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.